James Bhatt

James Bhatt is a pioneer in tumor-infiltrating lymphocyte therapy for metastatic melanoma and other solid tumors. His research has refined TIL expansion protocols that preserve polyclonal TCR diversity while achieving clinically effective cell numbers. He has established biomarker frameworks for predicting TIL therapy response based on tumor-reactive clonotype enrichment. His clinical trials have demonstrated complete and durable responses in metastatic melanoma patients refractory to checkpoint inhibitors.